ARTLARTELO BIOSCIENCES, INC.

Nasdaq artelobio.com


$ 1.38 $ -0.03 (-2.17 %)    

Friday, 03-May-2024 13:00:00 EDT
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 1.35
$ 1.38
$ 0.00 x 0
$ 0.00 x 0
$ 1.38 - $ 1.38
$ 1.15 - $ 2.98
5,058
na
4.36M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-25-2024 12-31-2023 10-K
2 11-13-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-11-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-09-2022 06-30-2022 10-Q
8 05-12-2022 03-31-2022 10-Q
9 01-12-2022 11-30-2021 10-Q
10 11-29-2021 08-31-2021 10-K
11 07-12-2021 05-31-2021 10-Q
12 04-13-2021 02-28-2021 10-Q
13 01-14-2021 11-30-2020 10-Q
14 11-04-2020 08-31-2020 10-K
15 07-13-2020 05-31-2020 10-Q
16 04-13-2020 02-29-2020 10-Q
17 01-14-2020 11-30-2019 10-Q
18 11-25-2019 08-31-2019 10-K
19 07-15-2019 05-31-2019 10-Q
20 04-15-2019 02-28-2019 10-Q
21 01-14-2019 11-30-2018 10-Q
22 11-29-2018 08-31-2018 10-K
23 07-13-2018 05-31-2018 10-Q
24 04-16-2018 02-28-2018 10-Q
25 01-16-2018 11-30-2017 10-Q
26 11-29-2017 08-31-2017 10-K
27 07-21-2017 05-31-2017 10-Q
28 04-14-2017 02-28-2017 10-Q
29 01-10-2017 11-30-2016 10-Q
30 11-29-2016 08-31-2016 10-K
31 07-05-2016 05-31-2016 10-Q
32 04-01-2016 02-29-2016 10-Q
33 01-14-2016 11-30-2015 10-Q
34 12-11-2015 08-31-2015 10-K
35 07-15-2015 05-31-2015 10-Q
36 04-14-2015 02-28-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino maintains Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pri...

 artelo-biosciences-earlier-reported-q4-eps-099-misses-056-estimate

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of ...

 artelo-biosciences-fy23-eps-314-vs-356-yoy

Fiscal 2023 Year-End Financial ResultsCash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023...

 artelo-biosciences-has-been-granted-european-patent-number-ep3723752-titled-new-solid-forms-of-cannabidiol-and-uses-thereof-for-various-medical-treatments

https://register.epo.org/application?number=EP18887462 

 artelo-biosciences-announces-publication-of-new-peer-reviewed-pre-clinical-research-demonstrating-art2612s-effectiveness-in-treating-and-preventing-oxaliplatin-induced-peripheral-neuropathy

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

 artelo-biosciences-announces-selection-of-worldwide-clinical-trials-as-clinical-research-organization-to-support-first-in-human-study-of-art2612

Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways...

 artelo-biosciences-filed-us-patent-application-20230404939-solid-forms-of-cannabidiol-and-uses-thereof

https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20230404939

 artelo-biosciences-presents-new-preclinical-data-on-art1211-at-the-4th-annual-med-cannabis-2023-conference-in-germany

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways ...

 hc-wainwright--co-reiterates-buy-on-artelo-biosciences-maintains-5-price-target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Artelo Biosciences (NASDAQ:ARTL) with a Buy and maintains $5 pr...

 artelo-biosciences-q3-eps-083-misses-065-estimate-129-m-in-cash-and-investments

Artelo Biosciences (NASDAQ:ARTL) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of ...

 artelo-biosciences-announces-publication-of-new-peer-reviewed-research-demonstrating-protective-properties-of-art2713-against-muscle-degeneration-caused-by-certain-cancers

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways ...

 artelo-biosciences-to-present-preclinical-data-showcasing-research-on-art2612-and-art1211-in-anxiety-and-depression-at-neuroscience-2023

Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION